EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Neurofilaments as Biomarkers of Disease Activity and Treatment Response in Spinal Muscular Atrophy

Sara Petrillo iD, Giorgia Coratti iD, Gianpaolo Cicala iD, Anna Capasso iD, Maddalena Bianchetti, Adele D Amico iD, Michela Catteruccia, Maria Sframeli iD, Antonio Trabacca iD, Concetta Palermo, Martina D Ambrosio, Romina Venditti and 15 more

European Journal of Neurology · 2026-11 · 33 (11)

DOI: 10.1111/ene.70797 ↗

At a glance

Journal article in European Journal of Neurology, published online on 2026-11-05. Written by Sara Petrillo and 26 co-authors. Institution: Muscular and Neurodegenerative Diseases Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Major MEDLINE topics: Neurofilament Proteins, Muscular Atrophy, Spinal. 39 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Unione europea-Next Generation EU-PNRR M6C2-Investimento 2.1 Valorizzazione e potenziamento della ricerca Biomedical.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Neurofilament light chain (NfL) has been increasingly used in spinal muscular atrophy (SMA) to monitor disease progression and treatment response.

Aims

We assessed plasma NfL before and after treatment with all three available therapies and in relation to SMA type, age, and functional level.

Methods

We included all consecutive individuals with SMA who initiated treatment or switched from one treatment to another in whom plasma samples were available at baseline and 12 months post‐treatment.

Results

Our study included 73 individuals, with Type I ( n = 13), II ( n = 19), III ( n = 33), IV SMA ( n = 1) or individuals diagnosed before clinical onset ( n = 7); 52/73 were treatment naïve and 21 were included at the time of switching to a new treatment. Mean age at baseline was 17 years, ranging from 0 to 47. At baseline, the NfL levels ranged from 4 to 2682 pg/mL. The overall 12‐month changes ranged from −2582.3 to 112 pg/mL. A significant decrease in NfL over time ( p < 0.001) was observed. Age was the strongest predictor of the magnitude of NfL reduction. The reduction was greatest in children < 2 years (83%), with progressively smaller reductions in older age groups. SMN2 copy number and SMA type had no significant interactions. Comparison among treatments was challenging because of cohorts' composition; in adults, risdiplam and nusinersen showed similar magnitudes of NfL changes.

Conclusions

Our findings expand the literature on NfL in SMA, providing additional data of their changes in response to all three therapies and across a wide spectrum of age and severity.

Subjects

MeSH terms (MEDLINE)

Neurofilament ProteinsMuscular Atrophy, SpinalHumansFemaleBiomarkersMaleChild, PreschoolChildInfantAdolescentAdultMiddle AgedYoung AdultTreatment OutcomeOligonucleotidesDisease ProgressionBenzamidesThiophenesInfant, NewbornAzo CompoundsPyrimidines

Author keywords

biomarkerdisease‐modifying therapiesneurofilamentspinal muscular atrophytreatment response

Substances

Neurofilament ProteinsBiomarkersneurofilament protein LOligonucleotidesnusinersenBenzamidesThiophenesRisdiplamAzo CompoundsPyrimidines

Authors and institutions

  • Muscular and Neurodegenerative Diseases Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Pediatric Neurology Unit, Catholic University, Rome, Italy.
  • Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
  • Unit for Severe Disabilities in Developmental Age and Young Adults (Developmental Neurology and Neurorehabilitation), Scientific Institute IRCCS E. Medea, Brindisi, Italy.
  • Unit of Medical Genetics, Department of Laboratory Science and Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

ORCID profiles: Sara Petrillo, Giorgia Coratti, Gianpaolo Cicala, Anna Capasso, Adele D Amico, Maria Sframeli, Antonio Trabacca, Laura Castellini, Martina Malaspina, Emanuela Abiusi, Danilo Tiziano, Stefania Corti, Matteo Garibaldi, Valeria A Sansone, Giacomo Comi, Fiorella Piemonte, Eugenio Mercuri

Funding

  • Unione europea-Next Generation EU-PNRR M6C2-Investimento 2.1 Valorizzazione e potenziamento della ricerca Biomedical

Cite

APA

Petrillo, S., Coratti, G., Cicala, G., Capasso, A., Bianchetti, M., D Amico, A., Catteruccia, M., Sframeli, M., Trabacca, A., Palermo, C., D Ambrosio, M., Venditti, R., Castellini, L., Malaspina, M., Abiusi, E., Tiziano, D., Corti, S., Garibaldi, M., Albamonte, E., …, & Mercuri, E. (2026). Neurofilaments as Biomarkers of Disease Activity and Treatment Response in Spinal Muscular Atrophy. European Journal of Neurology, 33(11). https://doi.org/10.1111/ene.70797

Vancouver

Petrillo S, Coratti G, Cicala G, Capasso A, Bianchetti M, D Amico A, et al. Neurofilaments as Biomarkers of Disease Activity and Treatment Response in Spinal Muscular Atrophy. European Journal of Neurology. 2026;33(11). doi:10.1111/ene.70797

BibTeX
@article{Petrillo2026,
  author = {Petrillo, Sara and Coratti, Giorgia and Cicala, Gianpaolo and Capasso, Anna and Bianchetti, Maddalena and D Amico, Adele and Catteruccia, Michela and Sframeli, Maria and Trabacca, Antonio and Palermo, Concetta and D Ambrosio, Martina and Venditti, Romina and Castellini, Laura and Malaspina, Martina and Abiusi, Emanuela and Tiziano, Danilo and Corti, Stefania and Garibaldi, Matteo and Albamonte, Emilio and Sansone, Valeria A and Romeo, Marika and Messina, Sonia and Pane, Marika and Comi, Giacomo and Bertini, Enrico and Piemonte, Fiorella and Mercuri, Eugenio},
  title = {Neurofilaments as Biomarkers of Disease Activity and Treatment Response in Spinal Muscular Atrophy},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {11},
  doi = {10.1111/ene.70797}
}
Start for free →